CellaVision AB (CHIX:CEVIS) Accounts Payable: kr40.7 Mil (As of Mar. 2026)


CHIX:CEVIS CellaVision AB CHIX:CEVIS
94 GF Score
Price kr160.20
GF Value kr249.12
! 1 Warning Sign
View Full Analysis

What is CellaVision AB Accounts Payable?

CellaVision AB CHIX:CEVIS 94 Accounts Payable is kr40.7 Mil as of Mar. 2026. GuruFocus rates CHIX:CEVIS with a GF Score™ of 94/100 and a GF Value™ of kr249.12. The stock has 1 warning sign investors should review.

CellaVision AB's Accounts Payable for the quarter that ended in Mar. 2026 was kr40.7 Mil.

CellaVision AB's quarterly Accounts Payable declined from Sep. 2025 (kr41.4 Mil) to Dec. 2025 (kr35.7 Mil) but then increased from Dec. 2025 (kr35.7 Mil) to Mar. 2026 (kr40.7 Mil).

CellaVision AB's annual Accounts Payable declined from Dec. 2023 (kr32.5 Mil) to Dec. 2024 (kr32.2 Mil) but then increased from Dec. 2024 (kr32.2 Mil) to Dec. 2025 (kr35.7 Mil).

CellaVision AB Accounts Payable Related Terms

CellaVision AB Accounts Payable Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Accounts Payable Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.86 47.86 32.53 32.22 35.73

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.82 41.94 41.40 35.73 40.74
CHIX:CEVIS
94GF Score
CellaVision AB CHIX:CEVIS
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of kr40.7 Mil mean?
CellaVision AB (CHIX:CEVIS) has a Accounts Payable of kr40.7 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on CellaVision AB and its competitors.
Is CellaVision AB's Accounts Payable too high?
CellaVision AB's current Accounts Payable is kr40.7 Mil. Overall, CellaVision AB has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Accounts Payable compare to ABT and SYK?
CellaVision AB's Accounts Payable of kr40.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on CellaVision AB and its competitors. CellaVision AB's current Accounts Payable is kr40.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Accounts Payable of kr40.7 Mil. The stock's GF Value™ is kr249.12, compared to a current price of kr160.20 — trading 35.7% below its estimated fair value. The current Accounts Payable is kr40.7 Mil. CellaVision AB's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Accounts Payable is kr40.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of kr160.20 is trading 35.7% below its estimated GF Value™ of kr249.12.

Key valuation signals for CHIX:CEVIS:

  • Accounts Payable: kr40.7 Mil
  • GF Value™: kr249.12 vs. price of kr160.20 (35.7% below fair value)
  • GF Score™: 94/100 with 1 warning sign

No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
94GF Score

Get the complete analysis for CHIX:CEVIS

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr160.20
Price
kr249.12
GF Value